Carmen J. Allegra

University of Florida Health — United States

Medicine · Health Sciences

75h-index22.5kcitations421works2.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(195), Genetic factors in colorectal cancer(73), Cancer Genomics and Diagnostics(56), Gastric Cancer Management and Outcomes(51), Cancer Treatment and Pharmacology(48)

Publications419 total

Changing standard of care during a randomized trial: examples, considerations and guidelines
JNCI Journal of the National Cancer Institute·2026
A novel framework to grade the quality of surrogate endpoints at the trial level: An analysis of surrogate endpoints used in colorectal cancer trials.
Journal of Clinical Oncology·2026
Phase 2 trial of CBX-12 for metastatic chemotherapy-refractory microsatellite stable colorectal cancer (ETCTN 10707).
Journal of Clinical Oncology·2026
Abstract B139: A panel of patient-derived organoid models from rare cancers for high-throughput preclinical pharmacology studies
Molecular Cancer Therapeutics·2025
Erratum: Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer
Journal of Clinical Oncology·2025
NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with “quadruple wild-type” (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutated
Cancer Chemotherapy and Pharmacology·2025
p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2+ breast cancer that limits trastuzumab deruxtecan efficacy
Nature Cancer·2025· 4 cited
Erratum: Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms
JCO Precision Oncology·2025Open Access
Abstract 1674: Combinatorial screen with standard of care and selected anticancer agents identifies multiple combinations with activity against a panel of patient-derived colorectal organoids
Cancer Research·2025
Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group
JCO Precision Oncology·2025· 3 cited
Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in patients with metastatic pancreatic cancer with germline BRCA1 or BRCA2 mutations: SWOG S2001 NCT04548752.
Journal of Clinical Oncology·2025· 3 cited
Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms
JCO Precision Oncology·2024· 11 citedOpen Access
A novel regimen for pancreatic ductal adenocarcinoma targeting MEK, BCL-xL, and EGFR
Neoplasia·2024· 5 citedOpen Access
Phase III Evaluation of Treatment Combinations in Three-Arm Trials
Journal of Clinical Oncology·2024· 3 cited
ETCTN 10366: A phase 1 study of DNA-PK inhibitor peposertib in combination with hypofractionated radiotherapy for the treatment of locally advanced pancreatic adenocarcinoma.
Journal of Clinical Oncology·2024
Correction: NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer
Breast Cancer Research·2024· 1 citedOpen Access
NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer
Breast Cancer Research·2024· 6 citedOpen Access
Abstract 7223: A triplet therapeutic strategy targeting MEK, BCL-XL, and EGFR, for KRAS-mutant pancreatic ductal adenocarcinoma
Cancer Research·2024
Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer
Journal of Clinical Oncology·2024· 15 citedOpen Access
A phase Ib/II study (IMMCO-1) of atezolizumab plus tivozanib in castrate-resistant prostate cancer and certain other immunologically cold tumors.
Journal of Clinical Oncology·2024
page 1 of 21Next →

Frequent Co-authors

Greg Yothers(17), Norman Wolmark(14), Michael J. O’Connell(11), J C Drake(11), Nicholas J. Petrelli(8), Linda H. Colangelo(7), Saima Sharif(7), Daniel J. Sargent(7), Bruce A. Chabner(7), Stanley R. Hamilton(6), Edward Chu(6), Patrick G. Johnston(5), Scott Kopetz(5), Christopher H. Lieu(5), Mark S. Roh(4), Richard M. Goldberg(4), Samia Lopa(4), R. Bryan Rumble(4), Eric Van Cutsem(3), Josep Tabernero(3)